GlassScriptPhysician profile
Joyce A Finlay
NPI 1952403586
$2,070.92
in general payments reported to CMS, 2019-2025
23 companies · $626 in 2025
The $626 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $395 · 2023: $227 · 2024: $688 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.69 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $463.19 | 2024 | Veozah |
| Mayne Pharma Commercial LLC | $450.09 | 2023-2025 | |
| Abbvie INC. | $201.07 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $124.19 | 2022 | |
| Organon LLC | $123.92 | 2021-2025 | Nexplanon |
| Viiv Healthcare Company | $69.90 | 2025 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $67.88 | 2021-2025 | |
| Evofem Biosciences, INC. | $62.92 | 2021-2025 | Phexxi, Solosec, Phexx |
| Sumitomo Pharma America, INC. | $62.61 | 2023-2024 | Myfembree |
| Exact Sciences Corporation | $59.04 | 2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $58.02 | 2021-2022 | |
| Aspira Women'S Health INC | $55.05 | 2024-2025 | Ova1 |
| Coopersurgical, INC. | $52.35 | 2022 | |
| Millicent US INC | $42.21 | 2025 | Femlyv |
| Shield Therapeutics INC | $29.52 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $26.10 | 2024 | Injectafer |
| Hologic Sales and Service, LLC | $21.96 | 2025 | Fetal Fibronectin Enzyme Immunoassay |
| Exeltis, USA INC. | $18.18 | 2023 | Slynd |
| Abbott Laboratories | $18.06 | 2025 | Alinity M |
| Mycovia Pharmaceuticals, INC. | $17.09 | 2023 | Vivjoa |
| Ascend Therapeutics US, LLC | $16.97 | 2023 | |
| Therapeuticsmd, INC. | $16.79 | 2021 | |
| Pfizer INC. | $13.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Finlay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.